Respectfully submitted by Meri Gibson
I am always reading and learning about our cohort and the journeys we travel in life. This piece of research inspired me to think more about what we go through post a diagnosis.
For every breast cancer survivor who has sat in a doctor's room waiting for answers, every new step toward kinder, more personalised treatment matters. A large international clinical trial has brought encouraging news: many people with a common type of breast cancer may be able to safely avoid chemotherapy, thanks to a gene test that helps identify who is likely to benefit from it and who is not.
The OPTIMA trial, led by University College London, followed more than 4,400 patients across the United Kingdom, Norway, Sweden, Australia, New Zealand, and Thailand. Researchers used a test called Prosigna to study the activity of genes involved in breast cancer growth and to estimate the risk of the cancer returning.
For many survivors, chemotherapy is remembered not only as a treatment, but as a season of exhaustion, nausea, hair loss, lowered immunity, fear, and uncertainty. It can be lifesaving, but it can also ask so much of the body, the mind, and the spirit.
That is why these findings feel so meaningful. In the trial, more than two-thirds of participants had a low Prosigna score and were treated without chemotherapy. After five years, their outcomes were remarkably close to those who did receive chemotherapy, suggesting that many patients may be spared unnecessary treatment without compromising their care.
For breast cancer survivor dragon boat paddlers, this news carries a special resonance. We know what it means to rebuild strength one stroke at a time. We know the power of gathering in a boat, placing our paddles in the water together, and moving forward as one. We know that survivorship is not only about living beyond cancer, but about reclaiming joy, courage, community, and confidence in our own bodies.
This research is not about taking chemotherapy away from those who need it. It is about making treatment decisions more precise, so that each person receives the care that is right for them. For those at higher risk, chemotherapy remains an important and powerful treatment. For others, this kind of testing may offer a path that avoids extra burden while still protecting their future.
Professor Rob Stein, chief investigator of the OPTIMA trial, described the findings as a crucial step toward personalised treatment. Rather than relying only on traditional measures such as tumour size or lymph node involvement, the trial used tumour biology to guide decisions about chemotherapy.
For survivors, that shift matters deeply. It means more people may be treated as individuals, not statistics. It means fewer people may face the physical and emotional weight of chemotherapy if it will not meaningfully help them. It means research is continuing to listen to what patients have always known: quality of life matters, too.
One trial participant, Karen Bonham from Cardiff, avoided chemotherapy after receiving a low Prosigna score and was treated with radiotherapy and hormone therapy instead. She described the results as an immense relief. Her words speak to a feeling many survivors understand: the longing for hope, clarity, and reassurance during one of life's most difficult chapters.
Another survivor, Tanya Hutson, who did receive chemotherapy as part of her treatment, called the new test "absolutely amazing" and described chemotherapy as brutal. Her response reminds us that progress in cancer care is built not only in laboratories and conference halls, but through the lived experiences of those who have endured treatment and still wish for a gentler path for others.
The findings are expected to help inform future decisions about access to testing and treatment guidelines. Researchers have noted that more evidence is still needed for people under 40, so this is not yet a complete answer for every patient. But it is a promising and compassionate step forward.
For those of us in the breast cancer dragon boat community, hope is something we understand in motion. It is in the drummer's call, the sweep's steady guidance, the splash of paddles entering together, and the quiet strength of the person beside us who knows without explanation what survival can cost.
This research adds another stroke to that journey forward. It tells us that science is learning to be more precise, more personal, and more humane. It reminds us that the future of breast cancer treatment is not only about longer lives, but fuller ones.
Every survivor's story is different. Every treatment decision belongs between a patient and their medical team. But news like this gives our community reason to lift our heads, breathe deeply and keep paddling.
Because we know this truth: healing is not always a straight course. Sometimes the water is rough. Sometimes the wind is against us. But together, with courage, knowledge, and hope, we keep moving forward.
One boat. One crew. One stroke at a time.
